San Diego-headquartered biotech firm Halozyme, which develops oncology and drug-delivery therapies, has named Albert Kildani as its new vice president of IR and corporate communications.
As well as serving as the primary contact for analysts and the investment community, Kildani now also ‘oversees all aspects of corporate communications, including public relations and external and internal communications,’ according to a press release announcing his appointment.
Dr Helen Torley, president and CEO of Halozyme, comments in the statement that Kildani, a former analyst, ‘brings deep experience, from both a company and an investor perspective. He will be a valuable addition as we continue to execute our two-pillar strategy, growing ENHANZE and preparing for the commercialization of PEGPH20.’
ENHANZE is the company’s drug delivery technology, for which it has developed partnerships with leading pharmaceutical companies including Roche, Pfizer, Janssen, AbbVie, Bristol-Myers Squibb and more. PEGPH20 is Halozyme’s ‘lead proprietary program’, an investigational drug that the firm says ‘applies a unique approach to targeting solid tumors.’
Kildani joins Halozyme from Vital Therapies, where he served as vice president of IR and business development, a role in which he was ‘responsible for the overall strategy and external messaging to institutional investors and performed due diligence on potential business development opportunities,’ according to the Halozyme statement. Prior to Vital Therapies, he held senior IR and corporate communications roles at Hologic and Gen-Probe. Before moving into IR, Kildani was a healthcare analyst, starting his career at Stark Investments.
